UriCon 50 mg
This page contains information on UriCon 50 mg for veterinary use.The information provided typically includes the following:
- UriCon 50 mg Indications
- Warnings and cautions for UriCon 50 mg
- Direction and dosage information for UriCon 50 mg
Uricon 50 Mg
This treatment applies to the following species:Phenylpropanolamine Hydrochloride
50 Mg Chewable Tablets
For Use In Dogs Only
UriCon 50 mg Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Description
UriCon chewable tablets contain 50 mg of phenylpropanolamine hydrochloride. Phenylpropanolamine is an α-adrenergic agonist which has been shown to increase urethral sphincter pressure in dogs. Loss of urethral sphincter tone and decreased sphincter pressure is associated with urinary incontinence in ovariohysterectomized or anestrous dogs.
UriCon 50 mg Indications
UriCon is indicated for the control of urinary incontinence caused by urethral sphincter incompetence in female dogs.
Dosage & Administration
The recommended dose of UriCon is 3 mg per kg body weight per day, divided into two or three equal oral doses. Some patients may achieve an adequate clinical response with a lower dose. Dosage may be rounded to the nearest 12.5 mg for practical dosing.
Warnings
Not for human use. Keep this and all drugs out of reach of children. UriCon should be avoided or used cautiously in dogs with glaucoma, cardiac disease, hypertension, renal insufficiency, and diabetes mellitus.
Precautions
UriCon should not be administered with other sympathomimetic drugs or tricyclic antidepressants, nor within two weeks of a monoamine oxidase inhibitor because of the risk of acute hypertension. UriCon may increase the risk of cardiac arrhythmias from halogenated gaseous anesthetics. Possible side-effects include restlessness, irritability, tachycardia, hypertension, and anorexia. It may take several days for the full benefit of the drug to be seen. Missed doses may negate the desired effect.
Adverse Reactions
Adverse reactions related to administration of UriCon may include restlessness, irritability, tachycardia, hypertension, urinary retention and anorexia.
Storage
Store between 2°-30°C (36°-86°F). Keep container tightly closed.
How Supplied
UriCon tablets are available in 60 count and 180 count bottles.
For Animal Use Only
Keep Out Of Reach Of Children
NEOGEN Vet™
Manufactured for Neogen® Corporation, Lexington, KY 40511 USA
For more information call: 859/254-1221
02236
L790-1104
|
Net Contents: |
NDC: |
Item No. |
|
|
60 tablets |
59051-9116-3 |
09116 |
010048 L787-1204 |
|
180 tablets |
59051-9116-0 |
09117 |
010049 L788-1204 |
Nac No.
14910620944 NANDINO BLVD, LEXINGTON, KY, 40511-1205
| Telephone: | 859-254-1221 | |
| Order Desk: | 800-525-2022 | |
| Fax: | 859-255-5532 | |
| Website: | www.neogen.com | |
| Email: | inform@neogen.com |
![]() |
Every effort has been made to ensure the accuracy of the UriCon 50 mg information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert. |
| Printable Version | Email Page |

